

ALASKA MEDICAID

**Pradaxa® (dabigatran)**

Capsule: 75mg and 150mg

**INDICATION:**

“PRADAXA is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation”<sup>1</sup>

**CRITERIA FOR APPROVAL:**

1. The patient has non-valvular atrial fibrillation; **AND**
2. The patient the patient is not taking warfarin or enoxaparin; **OR**
3. The patient was taking warfarin or enoxaparin but it is being discontinued.

**LENGTH OF AUTHORIZATION:**

1. Prior authorization may be approved for up to six (6) months.

**DISPENSING LIMIT:**

1. The dispensing limit is a thirty (30) days supply. **Caution:** Once a bottle of Pradaxa is opened the product must be used within 30 days.<sup>1</sup>

**REFERENCES / FOOTNOTES:**

<sup>1</sup> Pradaxa® package insert, available at: <<http://bidocs.boehringer-ingenheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf>> Accessed 3/1/2011.